<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365701</url>
  </required_header>
  <id_info>
    <org_study_id>Moti_FD_II</org_study_id>
    <nct_id>NCT02365701</nct_id>
  </id_info>
  <brief_title>Study of Motilitone to Treat Functional Dyspepsia</brief_title>
  <official_title>Double-blind, Placebo-controlled, Randomized, 4-week, Phase II Clinical Trial for Assessment of Efficacy and Safety of Motilitone in Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in
      patients with Functional Dyspepsia as measured by change in maximum tolerated volume and
      aggregate symptom score on the nutrient drink test.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maximum tolerated volume by nutrient drink test</measure>
    <time_frame>week -2, week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in aggregate symptom score by nutrient drink test</measure>
    <time_frame>week -2, week 4</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Motilitone 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motilitone 30mg</intervention_name>
    <description>30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks</description>
    <arm_group_label>Motilitone 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Subject fulfilling Rome III criteria for Functional Dyspepsia: They must have one
             or more of the following:

               1. Bothersome postprandial fullness

               2. Early satiation

               3. Epigastric pain

               4. Epigastric burning AND No evidence of structural disease at upper endoscopy
                  within last 3 months that is likely to explain the symptoms These must be
                  fulfilled for the last 3 months with symptom onset at least 6 months prior to
                  diagnosis.

          -  (2) At least a moderate or severe level within the previous 3 months for two of the
             following eight symptoms: upper abdominal pain, upper abdominal discomfort,
             postprandial fullness, upper abdominal bloating, early satiation, nausea, vomiting or
             excessive belching (each symptom rated as 0: None, 1: Mild, 2: Moderate, 3: Severe).

          -  (3) Subjects should be able to provide a written informed consent.

        Exclusion Criteria:

          -  (1) Subject currently on medication for another study or who participated in another
             clinical trial or study within 4 weeks before the start of this study.

          -  (2) Women of childbearing potential who are not using contraception and pregnant or
             lactating women.

          -  (3) Subject who had surgery that may affect gastrointestinal motility.

          -  (4) Subject with known history of gastric bleeding, intestinal obstruction or
             perforation.

          -  (5) Subject with known history of celiac disease, inflammatory bowel disease (Crohn's
             disease, ulcerative colitis) or microscopic colitis.

          -  (6) Subject who had any of the diseases such as reflux esophagitis, gastroduodenal
             ulcer, gastric adenocarcinoma, esophageal adenocarcinoma, pancreatic disease, etc.
             that may be an organic cause of dyspepsia.

          -  (7) Subject with liver dysfunction (serum glutamic oxaloacetic transaminase/serum
             glutamic pyruvic transaminase is at least 2.5 times higher than ULN).

          -  (8) Subject with renal dysfunction (Serum creatinine level is at least 1.5 times
             higher than ULN).

          -  (9) Subject with a serious cardiovascular (including known baseline QT prolongation
             defined by &gt;450 msec) or respiratory illness.

          -  (10) Subject with diagnosed psychotic illnesses, substance dependence or alcoholism.

          -  (11) Subject currently taking drugs that may affect gastrointestinal motility (e.g.,
             anticholinergic, Reglan, erythromycin, azithromycin, Domperidone, etc.), Buspirone,
             Acotiamide, Tramadol, nonsteroidal anti-inflammatory drug, systemic corticosteroids,
             and antidepressants, etc. within last 2 weeks of randomization.

          -  (12) Medications that can affect QT within last 2 weeks of randomization.

          -  (13) Subjects on herbal supplements for Functional Dyspepsia within last 2 weeks of
             randomization.

          -  (14) Subjects with gastric electric stimulator in place.

          -  (15) Subjects on narcotics or benzodiazepines within 7 days of randomization.

          -  (16) Subjects with score &gt; 12 for anxiety or depression on the Hospital Anxiety and
             Depression Scale (HADS).

          -  (17) Vulnerable study population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhusudan Grover, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

